WISARD (NEAT33) - Switch Study Mutation Ripivirine Dolutegravir

An open-label, multicentre, randomised, switch study to evaluate the virological efficacy over 96 weeks of 2-drug therapy with DTG/RPV FDC in antiretroviral treatment-experienced HIV-1 infected subjects virologically suppressed with NNRTIs resistance mutation K103N



Sponsor number: SSCR105/NEAT33 

EudraCT: 2017-004040-38 

Sponsor: NEAT ID 


Phase: IIIb


Indication:  HIV-1 infected patients with a history of virological failure to NNRTIs and having the K103N mutation


Countries: UK, France, Germany, Belgium, Spain, Italy


Status: Actively recruiting

Administrative office: NEAT ID Foundation, 27 Old Gloucester Street, London WC1N 3AX, UK

     e: NEAT-ID@NEAT-ID.org     

w: www.NEAT-ID.org

Registered address: PL 709  Rue Haute 322, 1000 Brussels, Belgium

©NEAT ID 2019